Cargando…
A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases
SIMPLE SUMMARY: It is known that drug transport barriers in the tumor determine drug concentration at the tumor site, causing disparity from the systemic (plasma) drug concentration. However, current clinical standard of care still bases dosage and treatment optimization on the systemic concentratio...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866038/ https://www.ncbi.nlm.nih.gov/pubmed/33503971 http://dx.doi.org/10.3390/cancers13030444 |
_version_ | 1783647987721830400 |
---|---|
author | Anaya, Daniel A. Dogra, Prashant Wang, Zhihui Haider, Mintallah Ehab, Jasmina Jeong, Daniel K. Ghayouri, Masoumeh Lauwers, Gregory Y. Thomas, Kerry Kim, Richard Butner, Joseph D. Nizzero, Sara Ramírez, Javier Ruiz Plodinec, Marija Sidman, Richard L. Cavenee, Webster K. Pasqualini, Renata Arap, Wadih Fleming, Jason B. Cristini, Vittorio |
author_facet | Anaya, Daniel A. Dogra, Prashant Wang, Zhihui Haider, Mintallah Ehab, Jasmina Jeong, Daniel K. Ghayouri, Masoumeh Lauwers, Gregory Y. Thomas, Kerry Kim, Richard Butner, Joseph D. Nizzero, Sara Ramírez, Javier Ruiz Plodinec, Marija Sidman, Richard L. Cavenee, Webster K. Pasqualini, Renata Arap, Wadih Fleming, Jason B. Cristini, Vittorio |
author_sort | Anaya, Daniel A. |
collection | PubMed |
description | SIMPLE SUMMARY: It is known that drug transport barriers in the tumor determine drug concentration at the tumor site, causing disparity from the systemic (plasma) drug concentration. However, current clinical standard of care still bases dosage and treatment optimization on the systemic concentration of drugs. Here, we present a proof of concept observational cohort study to accurately estimate drug concentration at the tumor site from mathematical modeling using biologic, clinical, and imaging/perfusion data, and correlate it with outcome in colorectal cancer liver metastases. We demonstrate that drug concentration at the tumor site, not in systemic circulation, can be used as a credible biomarker for predicting chemotherapy outcome, and thus our mathematical modeling approach can be applied prospectively in the clinic to personalize treatment design to optimize outcome. ABSTRACT: Chemotherapy remains a primary treatment for metastatic cancer, with tumor response being the benchmark outcome marker. However, therapeutic response in cancer is unpredictable due to heterogeneity in drug delivery from systemic circulation to solid tumors. In this proof-of-concept study, we evaluated chemotherapy concentration at the tumor-site and its association with therapy response by applying a mathematical model. By using pre-treatment imaging, clinical and biologic variables, and chemotherapy regimen to inform the model, we estimated tumor-site chemotherapy concentration in patients with colorectal cancer liver metastases, who received treatment prior to surgical hepatic resection with curative-intent. The differential response to therapy in resected specimens, measured with the gold-standard Tumor Regression Grade (TRG; from 1, complete response to 5, no response) was examined, relative to the model predicted systemic and tumor-site chemotherapy concentrations. We found that the average calculated plasma concentration of the cytotoxic drug was essentially equivalent across patients exhibiting different TRGs, while the estimated tumor-site chemotherapeutic concentration (eTSCC) showed a quadratic decline from TRG = 1 to TRG = 5 (p < 0.001). The eTSCC was significantly lower than the observed plasma concentration and dropped by a factor of ~5 between patients with complete response (TRG = 1) and those with no response (TRG = 5), while the plasma concentration remained stable across TRG groups. TRG variations were driven and predicted by differences in tumor perfusion and eTSCC. If confirmed in carefully planned prospective studies, these findings will form the basis of a paradigm shift in the care of patients with potentially curable colorectal cancer and liver metastases. |
format | Online Article Text |
id | pubmed-7866038 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78660382021-02-07 A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases Anaya, Daniel A. Dogra, Prashant Wang, Zhihui Haider, Mintallah Ehab, Jasmina Jeong, Daniel K. Ghayouri, Masoumeh Lauwers, Gregory Y. Thomas, Kerry Kim, Richard Butner, Joseph D. Nizzero, Sara Ramírez, Javier Ruiz Plodinec, Marija Sidman, Richard L. Cavenee, Webster K. Pasqualini, Renata Arap, Wadih Fleming, Jason B. Cristini, Vittorio Cancers (Basel) Article SIMPLE SUMMARY: It is known that drug transport barriers in the tumor determine drug concentration at the tumor site, causing disparity from the systemic (plasma) drug concentration. However, current clinical standard of care still bases dosage and treatment optimization on the systemic concentration of drugs. Here, we present a proof of concept observational cohort study to accurately estimate drug concentration at the tumor site from mathematical modeling using biologic, clinical, and imaging/perfusion data, and correlate it with outcome in colorectal cancer liver metastases. We demonstrate that drug concentration at the tumor site, not in systemic circulation, can be used as a credible biomarker for predicting chemotherapy outcome, and thus our mathematical modeling approach can be applied prospectively in the clinic to personalize treatment design to optimize outcome. ABSTRACT: Chemotherapy remains a primary treatment for metastatic cancer, with tumor response being the benchmark outcome marker. However, therapeutic response in cancer is unpredictable due to heterogeneity in drug delivery from systemic circulation to solid tumors. In this proof-of-concept study, we evaluated chemotherapy concentration at the tumor-site and its association with therapy response by applying a mathematical model. By using pre-treatment imaging, clinical and biologic variables, and chemotherapy regimen to inform the model, we estimated tumor-site chemotherapy concentration in patients with colorectal cancer liver metastases, who received treatment prior to surgical hepatic resection with curative-intent. The differential response to therapy in resected specimens, measured with the gold-standard Tumor Regression Grade (TRG; from 1, complete response to 5, no response) was examined, relative to the model predicted systemic and tumor-site chemotherapy concentrations. We found that the average calculated plasma concentration of the cytotoxic drug was essentially equivalent across patients exhibiting different TRGs, while the estimated tumor-site chemotherapeutic concentration (eTSCC) showed a quadratic decline from TRG = 1 to TRG = 5 (p < 0.001). The eTSCC was significantly lower than the observed plasma concentration and dropped by a factor of ~5 between patients with complete response (TRG = 1) and those with no response (TRG = 5), while the plasma concentration remained stable across TRG groups. TRG variations were driven and predicted by differences in tumor perfusion and eTSCC. If confirmed in carefully planned prospective studies, these findings will form the basis of a paradigm shift in the care of patients with potentially curable colorectal cancer and liver metastases. MDPI 2021-01-25 /pmc/articles/PMC7866038/ /pubmed/33503971 http://dx.doi.org/10.3390/cancers13030444 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Anaya, Daniel A. Dogra, Prashant Wang, Zhihui Haider, Mintallah Ehab, Jasmina Jeong, Daniel K. Ghayouri, Masoumeh Lauwers, Gregory Y. Thomas, Kerry Kim, Richard Butner, Joseph D. Nizzero, Sara Ramírez, Javier Ruiz Plodinec, Marija Sidman, Richard L. Cavenee, Webster K. Pasqualini, Renata Arap, Wadih Fleming, Jason B. Cristini, Vittorio A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases |
title | A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases |
title_full | A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases |
title_fullStr | A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases |
title_full_unstemmed | A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases |
title_short | A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases |
title_sort | mathematical model to estimate chemotherapy concentration at the tumor-site and predict therapy response in colorectal cancer patients with liver metastases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866038/ https://www.ncbi.nlm.nih.gov/pubmed/33503971 http://dx.doi.org/10.3390/cancers13030444 |
work_keys_str_mv | AT anayadaniela amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT dograprashant amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT wangzhihui amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT haidermintallah amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT ehabjasmina amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT jeongdanielk amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT ghayourimasoumeh amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT lauwersgregoryy amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT thomaskerry amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT kimrichard amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT butnerjosephd amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT nizzerosara amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT ramirezjavierruiz amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT plodinecmarija amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT sidmanrichardl amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT caveneewebsterk amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT pasqualinirenata amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT arapwadih amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT flemingjasonb amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT cristinivittorio amathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT anayadaniela mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT dograprashant mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT wangzhihui mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT haidermintallah mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT ehabjasmina mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT jeongdanielk mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT ghayourimasoumeh mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT lauwersgregoryy mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT thomaskerry mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT kimrichard mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT butnerjosephd mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT nizzerosara mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT ramirezjavierruiz mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT plodinecmarija mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT sidmanrichardl mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT caveneewebsterk mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT pasqualinirenata mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT arapwadih mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT flemingjasonb mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases AT cristinivittorio mathematicalmodeltoestimatechemotherapyconcentrationatthetumorsiteandpredicttherapyresponseincolorectalcancerpatientswithlivermetastases |